用维布妥昔单抗治疗蕈样肉芽肿：通过免疫组织化学和定量实时聚合酶链反应评估CD30表达 - Suppr

Treatment of mycosis fungoides with brentuximab vedotin: Assessing CD30 expression by immunohistochemistry and quantitative real-time polymerase chain reaction.

作者信息

Hofer Vivian, Maurus Katja, Houben Roland, Schrama David, Roth Sabine, Goebeler Matthias, Geissinger Eva, Rosenwald Andreas, Wobser Marion

机构信息

Department of Dermatology, Venereology, and Allergology, University Hospital Würzburg, Würzburg, Germany.

Institute of Pathology, University of Würzburg, Würzburg, Germany.

出版信息

J Cutan Pathol. 2022 Mar;49(3):314-317. doi: 10.1111/cup.14178. Epub 2021 Dec 22.

DOI:10.1111/cup.14178

PMID:34854114

Abstract

摘要

相似文献

Treatment of mycosis fungoides with brentuximab vedotin: Assessing CD30 expression by immunohistochemistry and quantitative real-time polymerase chain reaction.

J Cutan Pathol. 2022 Mar;49(3):314-317. doi: 10.1111/cup.14178. Epub 2021 Dec 22.

Response to brentuximab vedotin versus physician's choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis.

Eur J Cancer. 2021 May;148:411-421. doi: 10.1016/j.ejca.2021.01.054. Epub 2021 Mar 29.

RF - Brentuximab as Treatment for CD30 Primary Cutaneous Lymphoma.

Actas Dermosifiliogr (Engl Ed). 2019 Nov;110(9):769-770. doi: 10.1016/j.ad.2018.03.025. Epub 2019 May 28.

Poikilodermatous mycosis fungoides with CD30-positive large cell transformation successfully treated by brentuximab vedotin.

Dermatol Ther. 2020 Jan;33(1):e13152. doi: 10.1111/dth.13152. Epub 2019 Nov 19.

Impressive response of CD30-negative, treatment-refractory mycosis fungoides to brentuximab vedotin.

Dermatol Ther. 2019 Mar;32(2):e12835. doi: 10.1111/dth.12835. Epub 2019 Feb 17.

Mycosis fungoides: successful re-treatment with brentuximab vedotin.

Br J Dermatol. 2024 May 17;190(6):929-930. doi: 10.1093/bjd/ljae097.

Phase I/II clinical trial of brentuximab vedotin for pretreated Japanese patients with CD30-positive cutaneous T-cell lymphoma.

J Dermatol. 2024 Aug;51(8):1037-1049. doi: 10.1111/1346-8138.17324. Epub 2024 Jun 14.

Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project.

J Clin Oncol. 2015 Nov 10;33(32):3750-8. doi: 10.1200/JCO.2014.60.3969. Epub 2015 Jul 20.

Brentuximab vedotin in the treatment of CD30+ PTCL.

Blood. 2019 Dec 26;134(26):2339-2345. doi: 10.1182/blood.2019001821.

Brentuximab vedotin in CD30 primary cutaneous T-cell lymphomas: a review and analysis of existing data.

Int J Dermatol. 2017 Dec;56(12):1400-1405. doi: 10.1111/ijd.13696. Epub 2017 Aug 1.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Treatment of mycosis fungoides with brentuximab vedotin: Assessing CD30 expression by immunohistochemistry and quantitative real-time polymerase chain reaction.

J Cutan Pathol. 2022 Mar;49(3):314-317. doi: 10.1111/cup.14178. Epub 2021 Dec 22.

Response to brentuximab vedotin versus physician's choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis.

Eur J Cancer. 2021 May;148:411-421. doi: 10.1016/j.ejca.2021.01.054. Epub 2021 Mar 29.

RF - Brentuximab as Treatment for CD30 Primary Cutaneous Lymphoma.

Actas Dermosifiliogr (Engl Ed). 2019 Nov;110(9):769-770. doi: 10.1016/j.ad.2018.03.025. Epub 2019 May 28.

Poikilodermatous mycosis fungoides with CD30-positive large cell transformation successfully treated by brentuximab vedotin.

Dermatol Ther. 2020 Jan;33(1):e13152. doi: 10.1111/dth.13152. Epub 2019 Nov 19.

Impressive response of CD30-negative, treatment-refractory mycosis fungoides to brentuximab vedotin.

Dermatol Ther. 2019 Mar;32(2):e12835. doi: 10.1111/dth.12835. Epub 2019 Feb 17.

Mycosis fungoides: successful re-treatment with brentuximab vedotin.

Br J Dermatol. 2024 May 17;190(6):929-930. doi: 10.1093/bjd/ljae097.

Phase I/II clinical trial of brentuximab vedotin for pretreated Japanese patients with CD30-positive cutaneous T-cell lymphoma.

J Dermatol. 2024 Aug;51(8):1037-1049. doi: 10.1111/1346-8138.17324. Epub 2024 Jun 14.

Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project.

J Clin Oncol. 2015 Nov 10;33(32):3750-8. doi: 10.1200/JCO.2014.60.3969. Epub 2015 Jul 20.

Brentuximab vedotin in the treatment of CD30+ PTCL.

Blood. 2019 Dec 26;134(26):2339-2345. doi: 10.1182/blood.2019001821.

Brentuximab vedotin in CD30 primary cutaneous T-cell lymphomas: a review and analysis of existing data.

Int J Dermatol. 2017 Dec;56(12):1400-1405. doi: 10.1111/ijd.13696. Epub 2017 Aug 1.

Treatment of mycosis fungoides with brentuximab vedotin: Assessing CD30 expression by immunohistochemistry and quantitative real-time polymerase chain reaction.

作者信息

Hofer Vivian, Maurus Katja, Houben Roland, Schrama David, Roth Sabine, Goebeler Matthias, Geissinger Eva, Rosenwald Andreas, Wobser Marion

机构信息

Department of Dermatology, Venereology, and Allergology, University Hospital Würzburg, Würzburg, Germany.

Institute of Pathology, University of Würzburg, Würzburg, Germany.

出版信息

J Cutan Pathol. 2022 Mar;49(3):314-317. doi: 10.1111/cup.14178. Epub 2021 Dec 22.

DOI:10.1111/cup.14178

PMID:34854114

Abstract

摘要

Treatment of mycosis fungoides with brentuximab vedotin: Assessing CD30 expression by immunohistochemistry and quantitative real-time polymerase chain reaction.

作者信息

机构信息

出版信息

相似文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

Treatment of mycosis fungoides with brentuximab vedotin: Assessing CD30 expression by immunohistochemistry and quantitative real-time polymerase chain reaction.

作者信息

机构信息

出版信息